Tong Linjiang相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR Inhibitor

鞘氨醇-1-磷酸受体3赋予对第三代EGFR抑制剂耐药的肺癌肿瘤转移能力

影响因子:10.7

doi:10.1002/mco2.70744

Lai, Mengzhen; Chen, Jiaying; Qin, Ye; Zhang, Hui; Pan, Zilu; Zhang, Tao; Tong, Linjiang; Tang, Haotian; Bai, Gang; Liu, Qiupei; Li, Yan; Feng, Fang; Song, Peiran; Liu, Yingqiang; Chen, Yi; Fang, Yan; Tang, Bencan; Geng, Meiyu; Yu, Ker; Chen, Hao; Ding, Jian; Xie, Hua

发表日期：2026

文献求助收藏

Design, synthesis and pharmacological evaluation of 3H-spiro[benzofuran-2,4'-piperidine] IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma

3H-螺[苯并呋喃-2,4'-哌啶]IRAK4抑制剂的设计、合成及药理学评价及其在弥漫性大B细胞淋巴瘤治疗中的应用

期刊:RSC Medicinal Chemistry

影响因子:3.6

doi:10.1039/d6md00025h

Chen, Zhiwei; Zhang, Qi; Chen, Yun; Ning, Yi; Zhang, Q-I; Zhang, Mengxiao; Liu, Qiupei; Xue, Yi; Tong, Linjiang; Ding, Jian; Xie, Hua; Duan, Wenhu

免疫/内分泌

细胞生物学

发表日期：2026

文献求助收藏

Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma.

SYHA1813 双重靶向 VEGFR2 和 CSF1R 为治疗 BRAF 野生型和突变型黑色素瘤提供了一种新的策略

期刊:Cancer Cell International

doi:10.1186/s12935-025-03902-y

Shi Wenhao, Tang Haotian, Tong Linjiang, Song Peiran, Huang Yuqing, Wan Zhipeng, Huang Gege, Liu Qiupei, Zhan Zhengsheng, Zhou Yu, Li Yuantong, Wen Jiaxin, Tang Bencan, Duan Wenhu, Ding Jian, Li Xiaorui, Xie Hua

发表日期：2025

文献求助收藏

A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy

一种通过靶向肿瘤微环境并协同增强抗PD-1免疫疗法来治疗癌基因突变肿瘤的新策略

期刊:Cancer Communications

影响因子:24.9

doi:10.1002/cac2.12521

Liu, Yingqiang; Tong, Linjiang; Zhang, Mengge; Zhang, Qi; Liu, Qiupei; Feng, Fang; Li, Yan; Lai, Mengzhen; Tang, Haotian; Chen, Yi; Geng, Meiyu; Duan, Wenhu; Ding, Jian; Xie, Hua

肿瘤微环境

免疫/内分泌

发表日期：2024

文献求助收藏

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

更正：发现了一种新型第三代 EGFR 抑制剂，并确定了一种克服耐药性的潜在联合治疗策略。

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-023-01842-7

Zhang, Tao; Qu, Rong; Chan, Shingpan; Lai, Mengzhen; Tong, Linjiang; Feng, Fang; Chen, Hongyu; Song, Tingting; Song, Peiran; Bai, Gang; Liu, Yingqiang; Wang, Yanan; Li, Yan; Su, Yi; Shen, Yanyan; Sun, Yiming; Chen, Yi; Geng, Meiyu; Ding, Ke; Ding, Jian; Xie, Hua

发表日期：2023

文献求助收藏

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

更正：发现一种新型第三代 EGFR 抑制剂并确定克服耐药性的潜在联合治疗策略

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-021-01391-x

Zhang, Tao; Qu, Rong; Chan, Shingpan; Lai, Mengzhen; Tong, Linjiang; Feng, Fang; Chen, Hongyu; Song, Tingting; Song, Peiran; Bai, Gang; Liu, Yingqiang; Wang, Yanan; Li, Yan; Su, Yi; Shen, Yanyan; Sun, Yiming; Chen, Yi; Geng, Meiyu; Ding, Ke; Ding, Jian; Xie, Hua

发表日期：2021

文献求助收藏

Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors

核糖修饰的苯胺嘧啶衍生物作为EGFR酪氨酸激酶抑制剂的设计、合成和评价

期刊:Frontiers in Chemistry

影响因子:4.2

doi:10.3389/fchem.2017.00101

Hu, Xiuqin; Wang, Disha; Tong, Yi; Tong, Linjiang; Wang, Xia; Zhu, Lili; Xie, Hua; Li, Shiliang; Yang, You; Xu, Yufang

发表日期：2017

文献求助收藏

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.

AL3810 是一种多酪氨酸激酶抑制剂，通过靶向 VEGFR、FGFR 和 PDGFR 表现出强大的抗血管生成和抗肿瘤活性

期刊:Journal of Cellular and Molecular Medicine

影响因子:4.2

doi:10.1111/j.1582-4934.2012.01541.x

Zhou Yuanfeng, Chen Yi, Tong Linjiang, Xie Hua, Wen Weiwei, Zhang Jie, Xi Yong, Shen Yanyan, Geng Meiyu, Wang Yuanyuan, Jiang Hualiang, Luo Cheng, Lin Liping, Ding Jian

发表日期：2012

文献求助收藏

Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization

通过虚拟筛选和分级先导化合物优化，开发一类新型B-Raf(V600E)选择性抑制剂

期刊:Organic & Biomolecular Chemistry

影响因子:2.7

doi:10.1039/c2ob26081f

Kong, Xiangqian; Qin, Jie; Li, Zeng; Vultur, Adina; Tong, Linjiang; Feng, Enguang; Rajan, Geena; Liu, Shien; Lu, Junyan; Liang, Zhongjie; Zheng, Mingyue; Zhu, Weiliang; Jiang, Hualiang; Herlyn, Meenhard; Liu, Hong; Marmorstein, Ronen; Luo, Cheng

发表日期：2012

文献求助收藏

AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo

AST1306是一种新型的表皮生长因子受体1和2的不可逆抑制剂，在体外和体内均表现出抗肿瘤活性。

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0021487

Xie, Hua; Lin, Liping; Tong, Linjiang; Jiang, Yong; Zheng, Mingyue; Chen, Zhuo; Jiang, Xiaoyan; Zhang, Xiaowei; Ren, Xiaowei; Qu, Wenchao; Yang, Yang; Wan, Hua; Chen, Yi; Zuo, Jianping; Jiang, Hualiang; Geng, Meiyu; Ding, Jian

发表日期：2011

文献求助收藏